Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.40 |
| ▸ | TACR1 | P25103 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265100 | 1.00 | TRPM8 (0.41) | TRPM8MCHR1TACR1ALDH1A1LMNA | |
| SCHEMBL265131 | 0.89 | TACR1 (0.41) | MCHR1TACR1UTS2RMETMDM2 | |
| SCHEMBL265130 | 0.89 | TACR1 (0.41) | MCHR1TACR1UTS2RMETMDM2 | |
| SCHEMBL264379 | 0.83 | TACR1 (0.43) | MCHR1TACR1UTS2RSLC6A9MEN1 | |
| SCHEMBL264378 | 0.83 | TACR1 (0.43) | MCHR1TACR1UTS2RSLC6A9MEN1 | |
| SCHEMBL264380 | 0.83 | TACR1 (0.43) | MCHR1TACR1UTS2RSLC6A9MEN1 | |
| SCHEMBL265315 | 0.82 | TACR1 (0.41) | MCHR1TACR1UTS2RMDM2SLC6A9 | |
| SCHEMBL265316 | 0.82 | TACR1 (0.41) | MCHR1TACR1UTS2RMDM2SLC6A9 | |
| SCHEMBL265317 | 0.82 | TACR1 (0.41) | MCHR1TACR1UTS2RMDM2SLC6A9 | |
| SCHEMBL3647441 | 0.81 | TACR1 (0.45) | MCHR1TACR1UTS2RMDM2SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2297102-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | TRPM8 386/4885MCHR1 23/4885TACR1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.